BACKGROUND: Maspin is both overexpressed in tumors and inflammation, implicating a possible role in bridging inflammation and neoplasia. Idiopathic inflammatory bowel disease (IBD) and IBD-associated dysplasias and carcinomas represent a prototype for studying the relationship between chronic inflammatory states and neoplasia. AIM OF STUDY: To investigate expression of maspin in IBD and IBD-associated dysplasia and colorectal carcinoma. METHODS: Immunohistochemical labeling of maspin was examined using tissue microarrays constructed from archival biopsy and resection tissue from 90 patients with 125 histologically defined lesions including 30 with inactive chronic IBD, 51 with active chronic IBD, 4 IBD-associated foci with epithelial changes indefinite for dysplasia (IFD), 7 with IBD-associated low-grade epithelial dysplasia (LGD), 8 with IBD-associated high grade epithelial dysplasia (HGD), and 25 with IBD-associated invasive colorectal adenocarcinomas. RESULTS: Maspin was expressed in 47/51 (92%) active chronic IBD lesions, which was significantly higher than both inactive chronic IBD (13/30, 43%) and normal mucosa (1 of 9, 11%) (p < 0.01); in particular, the diffuse pattern of maspin expression was significantly higher in active IBD (41/51, 80%), compared with inactive IBD (5/30, 17%) and normal mucosa (0%) (p < 0.01). In the multistage progression model of colitis-associated neoplasia, aberrant labeling was observed at the earliest stages, with 3/4 (75%) IFD foci, 6/7 (86%) LGD, and 8/8 (100%) HGD specimens expressing maspin, virtually always in a diffuse pattern. Expectedly, 22/25 (88%) of invasive IBD-associated cancers overexpressed maspin, including 21 with diffuse labeling. CONCLUSIONS: Maspin is significantly overexpressed in both active IBD and colitis-associated dysplasia compared to either inactive IBD or normal colonic mucosa, suggesting a potential role in disease "flare" as well as neoplastic progression. Targeting maspin for control of disease activity and cancer prophylaxis may be a promising novel therapeutic strategy for IBD.
BACKGROUND:Maspin is both overexpressed in tumors and inflammation, implicating a possible role in bridging inflammation and neoplasia. Idiopathic inflammatory bowel disease (IBD) and IBD-associated dysplasias and carcinomas represent a prototype for studying the relationship between chronic inflammatory states and neoplasia. AIM OF STUDY: To investigate expression of maspin in IBD and IBD-associated dysplasia and colorectal carcinoma. METHODS: Immunohistochemical labeling of maspin was examined using tissue microarrays constructed from archival biopsy and resection tissue from 90 patients with 125 histologically defined lesions including 30 with inactive chronic IBD, 51 with active chronic IBD, 4 IBD-associated foci with epithelial changes indefinite for dysplasia (IFD), 7 with IBD-associated low-grade epithelial dysplasia (LGD), 8 with IBD-associated high grade epithelial dysplasia (HGD), and 25 with IBD-associated invasive colorectal adenocarcinomas. RESULTS:Maspin was expressed in 47/51 (92%) active chronic IBD lesions, which was significantly higher than both inactive chronic IBD (13/30, 43%) and normal mucosa (1 of 9, 11%) (p < 0.01); in particular, the diffuse pattern of maspin expression was significantly higher in active IBD (41/51, 80%), compared with inactive IBD (5/30, 17%) and normal mucosa (0%) (p < 0.01). In the multistage progression model of colitis-associated neoplasia, aberrant labeling was observed at the earliest stages, with 3/4 (75%) IFD foci, 6/7 (86%) LGD, and 8/8 (100%) HGD specimens expressing maspin, virtually always in a diffuse pattern. Expectedly, 22/25 (88%) of invasive IBD-associated cancers overexpressed maspin, including 21 with diffuse labeling. CONCLUSIONS:Maspin is significantly overexpressed in both active IBD and colitis-associated dysplasia compared to either inactive IBD or normal colonic mucosa, suggesting a potential role in disease "flare" as well as neoplastic progression. Targeting maspin for control of disease activity and cancer prophylaxis may be a promising novel therapeutic strategy for IBD.
Authors: H Kimura; S Miura; T Shigematsu; N Ohkubo; Y Tsuzuki; I Kurose; H Higuchi; Y Akiba; R Hokari; M Hirokawa; H Serizawa; H Ishii Journal: Dig Dis Sci Date: 1997-05 Impact factor: 3.199
Authors: Z Zou; A Anisowicz; M J Hendrix; A Thor; M Neveu; S Sheng; K Rafidi; E Seftor; R Sager Journal: Science Date: 1994-01-28 Impact factor: 47.728
Authors: Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes Journal: Gastroenterology Date: 2004-02 Impact factor: 22.682
Authors: Sharon L Swierczynski; Anirban Maitra; Susan C Abraham; Christine A Iacobuzio-Donahue; Raheela Ashfaq; John L Cameron; Richard D Schulick; Charles J Yeo; Ayman Rahman; David A Hinkle; Ralph H Hruban; Pedram Argani Journal: Hum Pathol Date: 2004-03 Impact factor: 3.466
Authors: Alberto Muñoz-Prieto; Maria Dolores Contreras-Aguilar; Jose Joaquín Cerón; Ignacio Ayala; Maria Martin-Cuervo; Juan Carlos Gonzalez-Sanchez; Stine Jacobsen; Josipa Kuleš; Anđelo Beletić; Ivana Rubić; Vladimir Mrljak; Fernando Tecles; Sanni Hansen Journal: Animals (Basel) Date: 2022-05-02 Impact factor: 3.231
Authors: Ing-Marie Viklund; Nikolai V Kuznetsov; Robert Löfberg; Marco Daperno; Raffaello Sostegni; Marco Astegiano; Mario Rizzetto; Oliver von Stein; Mauro D'Amato; Petra von Stein; Sven Pettersson Journal: Int J Colorectal Dis Date: 2008-07-25 Impact factor: 2.571
Authors: Daniel Drev; Andrea Bileck; Christopher Gerner; Brigitte Marian; Zeynep N Erdem; Thomas Mohr; Gerald Timelthaler; Andrea Beer Journal: Clin Proteomics Date: 2017-10-06 Impact factor: 3.988